Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40X9V | ISIN: US47100L3015 | Ticker-Symbol:
NASDAQ
21.01.25
17:05 Uhr
6,410 US-Dollar
+0,300
+4,91 %
1-Jahres-Chart
JANOVER INC Chart 1 Jahr
5-Tage-Chart
JANOVER INC 5-Tage-Chart
GlobeNewswire (Europe)
47 Leser
Artikel bewerten:
(0)

Janover Inc.: Janover Announces 190%+ Growth of AI Enabled Software Business

Finanznachrichten News

BOCA RATON, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Janover Inc. (Nasdaq: JNVR) ("Janover" or the "Company"), an AI-enabled platform connecting the commercial real estate industry, today announced the exciting, continued growth of its AI SaaS and marketplace platform for the multifamily and commercial real estate industry. Blake Janover, CEO of Janover, stated, "The numbers speak for themselves. We started the year and said that we're going to lean into our software business and pivot to a SaaS model that provides an enduring value to our client and compounding growth to our shareholders, allowing us to invest further into the value we drive to our customers. We grew our ARR from subscription revenue by more than 190% over last year and approximately 65% sequentially in the fourth quarter ended December 31, 2024. As we continue to enhance our services with embedded AI and better and more useful data and tools, we think the market ought to start valuing us a little differently; but either way, we're playing the long game here."

Our SaaS products Include:

  • Janover Pro: (pro.janover.co) What we believe to be the most complete SaaS marketplace connecting commercial mortgage and capital markets professionals, owners and developers with thousands of commercial real estate lenders. Value-add services include concierge capital markets advisory as well.
  • Janover Engage: (engage.janover.co) The premier marketplace for real estate GPs and syndicators using Reg D 506(c) to connect with and raise capital from accredited investors including family offices, institutions, HNW (high net worth), and UNHW (ultra-high net worth) individuals.
  • Janover Connect: (connect.janover.co) What we believe is the fastest and easiest customer-centric platform for real estate syndicators and GPs to manage and serve their investors with tools like an investor CRM, investor portal, K-1 distributions, deal management, and more.

According to our customers our SaaS products are making an impact in our ecosystem. Some examples are:

  • Greg Loudon, an independent commercial mortgage broker, says: "Janover Pro has been invaluable in connecting me with a range of lenders I might not have discovered otherwise. The support I've received has been outstanding; they actively seek feedback and have implemented some of my suggestions. It's reassuring to know they truly listen to their customers."
  • Brian Brady from a middle market capital markets firm says after using Janover Pro just a short time: "Since starting, I sourced (and originated) a bridge loan and have over 7 LOIs for an SBA 7A loan for a purchase of a day care facility."
  • East West Partners' Mary Beth Knelson praises how Janover Connect has streamlined their syndication operations: "The platform has transformed our annual K-1 distributions. The platform is user friendly, intuitive, and robust. The customer service and support are exceptional!"

Janover Engage continues to build traction. One of the very first deals listed on Janover Engage led to an experienced GP (General Partner) receiving introductions to 100 new accredited investors in under eight weeks.

About Janover Inc.

Janover is an AI-enabled platform that connects the commercial real estate industry. The company serves over one million annual web users and 1,000+ lenders, including more than 10% of U.S. banks in America, providing debt capital markets services, real estate syndication software, data and AI licensing, and insurance brokerage solutions to entrepreneurial multifamily and commercial real estate owners, developers and professionals. Janover operates through its Debt, Equity, and Insurance divisions, focusing on delivering needed technology-first solutions to commercial real estate professionals. Additional information about the Company is available at: https://janover.co/.

To view the latest investor presentation, please visit https://ir.janover.co/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," strategy," "future," "likely," "may,", "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the effect of and uncertainties related the ongoing volatility in interest rates; (ii) our ability to achieve and maintain profitability in the future; (iii) the impact on our business of the regulatory environment and complexities with compliance related to such environment; (iv) our ability to respond to general economic conditions; (v) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (vi) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and other risks and uncertainties more fully in the section captioned "Risk Factors" in the Company's Registration Statement on Form 1-A related to the public offering (SEC File No. 024-12458) and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact:
Bruce S. Rosenbloom, CFO
Tel: (561) 782-2788
Email: IR@janover.co


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.